(Premarket story updated with BMO, Marshall & Ilsey news, share price changes)
NEW YORK (TheStreet) -- BMO Financial (BMO) - Get Report has agreed to buy Marshall & Ilsley( MI) for $4.1 billion.

Shares of BMO have fallen 2.7% to $59.99, while Marshall & Ilsley has surged by 23.8% to $7.17.

>> Bank of Montreal to Buy Marshall & Ilsley

European regulators breathed new life into

InterMune

(ITMN)

Friday, recommending the approval of the company's drug Esbriet as a treatment for the fatal lung disease idiopathic pulmonary fibrosis.

Shares of the company surged by 113.5% to $30.47 in premarket trading Friday.

>> InterMune: EU to OK Esbriet Lung Drug

Massey Energy

( MEE) is exploring options ranging from a sale of the company to a takeover of

International Coal Group

( ICO),

Bloomberg

reports.

Massey shares were flat at $50.70, while International Coal has popped by 5.9% to $7.39.

>> Massey Eyeing International Coal: Report

Oracle

(ORCL) - Get Report

posted fiscal second-quarter adjusted profit of $2.6 billion, or 51 cents a share, on revenue of $8.65 billion for the quarter ended Nov. 30. The performance topped the average estimate of analysts polled by Thomson Reuters for earnings of 46 cents a share on revenue of $8.34 billion.

Shares of the company popped by 4.1% to $31.52 in premarket trading.

>> RIM, Oracle, Take-Two: After-Hours Trading

Research In Motion

( RIMM) said it earned $911.1 million, or $1.74 a share, in its fiscal third quarter. The per-share figure was up 58% from its profit of $1.10 a share in the same period a year earlier and a dime above the average estimate of analysts polled by Thomson Reuters for earnings of $1.64 a share.

Shares of Research In Motion rose 2.7% to $60.85.

>> RIM, Oracle, Take-Two: After-Hours Trading

Accenture

(ACN) - Get Report

lifted its full-year forecast to earnings of $3.08 to $3.16 a share on a revenue increase of 8% to 11% vs. previously expected earnings of $3 to $3.08 a share on a revenue increase of 7% to 10%. Revenue for the current quarter is expected to be in the range of $5.6 billion to $5.8 billion, vs. the analyst consensus of $5.58 billion.

Accenture shares rose 4.2% to $48.62.

Shares of

MasterCard

(MA) - Get Report

and

Visa

(V) - Get Report

have regained their footing after plummeting on the

Federal Reserve's

issuance of two alternative fee structures in determining "reasonable and proportional" debit interchange fees -- each of which suggesting a fee cap of 12 cents a transaction.

Shares of MasterCard rose 2.2% to $228.29, while Visa was up 1.9% to $68.47.

>> Fed Proposes Debit Fee Cap

AstraZeneca

(AZN) - Get Report

wasn't able to obtain approval for its heart medicine Brilinta from the Food and Drug Administration, which has asked for more analysis on clinical trial results.

Shares of the company fell 5.4% to $46.58.

-- Written by Andrea Tse in New York.

>To contact the writer of this article, click here:

Andrea Tse

.

>To follow the writer on Twitter, go to

Andrea Tse

.

>To submit a news tip, send an email to:

tips@thestreet.com

.

RELATED STORIES:

>> Bank of Montreal to Buy Marshall & Ilsley

>> Massey Eyeing International Coal: Report

>> InterMune: EU to OK Esbriet Lung Drug

>> Stock Futures: Dec. 17

>> RIM, Oracle, Take-Two: After-Hours Trading

>> Fed Proposes Debit Fee Cap

Copyright 2010 TheStreet.com Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.